.png){kind=icon}
.png){kind=icon}
Return
Colchicine for Prevention of Perioperative Atrial Fibrillation and Myocardial Injury After Major Thoracic Surgery: Surgical Subgroup Analyses From the COP-AF Trial
.png){kind=icon}
PRE
AI
M
P
E
G
C
J
F
J
M
E
F
J
G
W
S
S
C
D
Y
S
V
D
DOI：10.1093/ejcts/ezag190.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Colchicine is a potent and inexpensive anti-inflammatory agent. Perioperative atrial fibrillation (POAF) and myocardial injury after noncardiac surgery (MINS) are 2 frequent cardiovascular complications after thoracic surgery, with acute surgical inflammation likely playing an important mechanistic role for both. The “COlchicine for the Prevention of Perioperative Atrial Fibrillation” (COP-AF) trial tested whether colchicine prevents POAF or MINS in patients undergoing thoracic surgery. The trial showed no significant difference in new clinically important POAF and MINS at 14 days after randomization.1 However, patients who underwent thoracoscopic surgery had a lower incidence of POAF and MINS compared to those who underwent open or conversion-to-open surgery. We undertook exploratory analyses of COP-AF to assess whether different surgical approaches modified the efficacy of colchicine for the POAF and MINS prevention.
Journal
E
IF:
3
Papers:
1.5W
Citations:
1.7W
Organization
Cited Papers